Merck & Company, Inc. (MRK) Shares Sold by Grandfield & Dodd LLC

Grandfield & Dodd LLC trimmed its holdings in Merck & Company, Inc. (NYSE:MRK) by 0.5% in the second quarter, according to its most recent disclosure with the SEC. The fund owned 343,022 shares of the company’s stock after selling 1,750 shares during the period. Merck & accounts for approximately 2.6% of Grandfield & Dodd LLC’s portfolio, making the stock its 7th largest position. Grandfield & Dodd LLC’s holdings in Merck & were worth $21,984,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. HM Capital Management LLC raised its holdings in Merck & by 0.4% during the first quarter. HM Capital Management LLC now owns 3,734 shares of the company’s stock worth $236,000 after purchasing an additional 15 shares in the last quarter. RB Capital Management LLC raised its holdings in Merck & by 0.5% during the second quarter. RB Capital Management LLC now owns 4,587 shares of the company’s stock worth $294,000 after purchasing an additional 23 shares in the last quarter. Baystate Wealth Management LLC raised its holdings in Merck & by 0.4% during the second quarter. Baystate Wealth Management LLC now owns 6,470 shares of the company’s stock worth $405,000 after purchasing an additional 27 shares in the last quarter. Bath Savings Trust Co raised its holdings in Merck & by 0.5% during the second quarter. Bath Savings Trust Co now owns 5,427 shares of the company’s stock worth $348,000 after purchasing an additional 28 shares in the last quarter. Finally, City Holding Co. raised its holdings in Merck & by 0.4% during the first quarter. City Holding Co. now owns 7,767 shares of the company’s stock worth $494,000 after purchasing an additional 31 shares in the last quarter. 72.91% of the stock is owned by institutional investors and hedge funds.

MRK has been the subject of several analyst reports. UBS AG increased their price target on shares of Merck & from $70.00 to $72.00 and gave the stock a “buy” rating in a report on Monday, July 31st. Piper Jaffray Companies set a $70.00 price target on shares of Merck & and gave the stock a “buy” rating in a report on Saturday, July 29th. BMO Capital Markets reissued a “buy” rating and set a $74.00 price target on shares of Merck & in a report on Tuesday, June 27th. Credit Suisse Group reissued a “buy” rating on shares of Merck & in a report on Tuesday, June 13th. Finally, BidaskClub raised shares of Merck & from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $69.81.

COPYRIGHT VIOLATION NOTICE: This news story was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://ledgergazette.com/2017/10/11/merck-company-inc-mrk-shares-sold-by-grandfield-dodd-llc.html.

Merck & Company, Inc. (NYSE MRK) opened at 64.46 on Wednesday. Merck & Company, Inc. has a 12 month low of $58.29 and a 12 month high of $66.80. The firm’s 50-day moving average is $64.42 and its 200 day moving average is $63.70. The firm has a market capitalization of $175.81 billion, a price-to-earnings ratio of 34.90 and a beta of 0.80.

Merck & (NYSE:MRK) last issued its quarterly earnings data on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.87 by $0.14. The firm had revenue of $9.93 billion for the quarter, compared to the consensus estimate of $9.75 billion. Merck & had a net margin of 17.14% and a return on equity of 26.02%. Merck &’s quarterly revenue was up .9% compared to the same quarter last year. During the same period last year, the firm posted $0.93 EPS. Equities analysts predict that Merck & Company, Inc. will post $3.87 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, October 6th. Shareholders of record on Friday, September 15th were given a dividend of $0.47 per share. The ex-dividend date was Thursday, September 14th. This represents a $1.88

Other large investors have also made changes to their positions in the company. HM Capital Management LLC raised its holdings in Merck & by 0.4% during the first quarter. HM Capital Management LLC now owns 3,734 shares of the company’s stock worth $236,000 after purchasing an additional 15 shares in the last quarter. RB Capital Management LLC raised its holdings in Merck & by 0.5% during the second quarter. RB Capital Management LLC now owns 4,587 shares of the company’s stock worth $294,000 after purchasing an additional 23 shares in the last quarter. Baystate Wealth Management LLC raised its holdings in Merck & by 0.4% during the second quarter. Baystate Wealth Management LLC now owns 6,470 shares of the company’s stock worth $405,000 after purchasing an additional 27 shares in the last quarter. Bath Savings Trust Co raised its holdings in Merck & by 0.5% during the second quarter. Bath Savings Trust Co now owns 5,427 shares of the company’s stock worth $348,000 after purchasing an additional 28 shares in the last quarter. Finally, City Holding Co. raised its holdings in Merck & by 0.4% during the first quarter. City Holding Co. now owns 7,767 shares of the company’s stock worth $494,000 after purchasing an additional 31 shares in the last quarter. 72.91% of the stock is owned by institutional investors and hedge funds.

MRK has been the subject of several analyst reports. UBS AG increased their price target on shares of Merck & from $70.00 to $72.00 and gave the stock a “buy” rating in a report on Monday, July 31st. Piper Jaffray Companies set a $70.00 price target on shares of Merck & and gave the stock a “buy” rating in a report on Saturday, July 29th. BMO Capital Markets reissued a “buy” rating and set a $74.00 price target on shares of Merck & in a report on Tuesday, June 27th. Credit Suisse Group reissued a “buy” rating on shares of Merck & in a report on Tuesday, June 13th. Finally, BidaskClub raised shares of Merck & from a “sell” rating to a “hold” rating in a report on Tuesday, August 1st. Two investment analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $69.81.

COPYRIGHT VIOLATION NOTICE: This news story was published by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this news story on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The legal version of this news story can be viewed at https://ledgergazette.com/2017/10/11/merck-company-inc-mrk-shares-sold-by-grandfield-dodd-llc.html.

Merck & Company, Inc. (NYSE MRK) opened at 64.46 on Wednesday. Merck & Company, Inc. has a 12 month low of $58.29 and a 12 month high of $66.80. The firm’s 50-day moving average is $64.42 and its 200 day moving average is $63.70. The firm has a market capitalization of $175.81 billion, a price-to-earnings ratio of 34.90 and a beta of 0.80.

Merck & (NYSE:MRK) last issued its quarterly earnings data on Friday, July 28th. The company reported $1.01 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.87 by $0.14. The firm had revenue of $9.93 billion for the quarter, compared to the consensus estimate of $9.75 billion. Merck & had a net margin of 17.14% and a return on equity of 26.02%. Merck &’s quarterly revenue was up .9% compared to the same quarter last year. During the same period last year, the firm posted $0.93 EPS. Equities analysts predict that Merck & Company, Inc. will post $3.87 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Friday, October 6th. Shareholders of record on Friday, September 15th were given a dividend of $0.47 per share. The ex-dividend date was Thursday, September 14th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.92%. Merck &’s dividend payout ratio (DPR) is 76.11%.

About Merck &

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services and Alliances. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Institutional Ownership by Quarter for Merck & (NYSE:MRK)

Receive News & Ratings for Merck & Company Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Company Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply